Nicholas Alexander Pickersgill

Nicholas Alexander Pickersgill

Auto-generated profile, based on publicly available information

Nicholas Alexander Pickersgill

Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Urology
Verified
Journal Article
Closed access
HLH. Henry Lai
H. Henry Lai
NPNicholas A. Pickersgill
Nicholas A. Pickersgill
JVJoel M. Vetter
Joel M. Vetter
Purpose:To compare demographics, clinical presentation, comorbidities, urinary profiles, and treatment responses between interstitial cystitis/bladder pain syndrome (IC/BPS) patients with and witho...

1 March 2020 in European Urology Focus
Verified
Journal Article
Closed access
NPNicholas A. Pickersgill
Nicholas A. Pickersgill
JVJoel M. Vetter
Joel M. Vetter
GAGerald L. Andriole
Gerald L. Andriole
ASAnup S. Shetty
Anup S. Shetty
KFKathryn J. Fowler
Kathryn J. Fowler
EKEric H. Kim
Eric H. Kim

1 December 2020 in Journal of Endourology
Verified
Journal Article
Closed access
NPNicholas Alexander Pickersgill
Nicholas Alexander Pickersgill
JVJoel M. Vetter
Joel M. Vetter
EKEric H. Kim
Eric H. Kim
SCSky J. Cope
Sky J. Cope
KDKefu Du
Kefu Du
RFR. Sherburne Figenshau
R. Sherburne Figenshau
Introduction: Percutaneous cryoablation (PCA) has emerged as an alternative to extirpative management of small renal masses (SRMs) in select patients, with a reduced risk of perioperative complications. Although disease recurrence is thought to occur in the early postoperative period, limited data on long-term oncologic outcomes have been published. We reviewed our 10-year experience with PCA for SRMs and assessed predictors of disease progression. Materials and Methods: We reviewed our prospectively maintained database of patients who underwent renal PCA from March 2005 to December 2015 ( n = 308). Baseline patient and tumor variables were recorded, and postoperative cross-sectional imaging was examined for evidence of disease recurrence. Disease progression was defined as the presence of local recurrence or new lymphadenopathy/metastasis. Results: Mean patient age was 67.2 ± 11 years, mean tumor size was 2.7 ± 1.3 cm, and mean nephrometry score was 6.8 ± 1.7. At mean follow-up of 38 months, local recurrence and new lymphadenopathy/metastasis occurred in 10.1% (31/308) and 6.2% (19/308) of patients, respectively. Excluding patients with a solitary kidney and/or von Hippel–Lindau, local recurrence and new lymphadenopathy/metastasis occurred in 8.6% (23/268) and 1.9% (5/268) of cases, respectively. Kaplan–Meier estimated disease-free survival was 92.5% at 1 year, 89.3% at 2 years, and 86.7% at 3 years post-PCA. Increasing tumor size was a significant predictor of disease progression (hazard ratio 1.32 per 1-cm increase in size, p = 0.001). Conclusions: PCA is a viable treatment option for patients with SRMs. Increasing tumor size is a significant predictor of disease progression following PCA.

1 January 2016 in The American Journal of Pathology
Verified
Journal Article
Closed access
DVDaniel E. Venegas-Pino
Daniel E. Venegas-Pino
PWPei-Wen Wang
Pei-Wen Wang
HSHeidi K. Stoute
Heidi K. Stoute
NSNicholas A. Singh-Pickersgill
Nicholas A. Singh-Pickersgill
BHBrian Y. Hong
Brian Y. Hong
GWGeoff Werstuck
Geoff Werstuck

1 May 2019 in Urology
Verified
Journal Article
Closed access
NPNicholas A. Pickersgill
Nicholas A. Pickersgill
JVJoel M. Vetter
Joel M. Vetter
NRNeel S. Raval
Neel S. Raval
GAGerald L. Andriole
Gerald L. Andriole
ASAnup S. Shetty
Anup S. Shetty
EKEric H. Kim
Eric H. Kim

31 May 2023 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
JBJames M. Berry
James M. Berry
HHHayden Hill
Hayden Hill
JVJoel M. Vetter
Joel M. Vetter
SBSam B. Bhayani
Sam B. Bhayani
GHGrant Henning
Grant Henning
EKEric H. Kim
Eric H. Kim